全球血液筛检市场规模、份额、趋势和成长分析报告（2026-2034年）

预计血液筛检市场规模将从 2025 年的 38.8 亿美元成长到 2034 年的 113.1 亿美元，2026 年至 2034 年的复合年增长率为 12.62%。

由于感染疾病流行以及对安全输血的需求不断增长，血液筛检市场预计将迎来显着成长。血液筛检是确保血液製品安全的关键流程，它透过检测病原体、抗体和其他有害物质来实现这一目标。随着医疗机构将病患安全放在首位，监管机构也加强了检测要求，先进血液筛检技术的应用预计将会增加。市场正朝着更有效率、更准确的检测方法转变，例如核酸检测 (NAT) 和多重检测，这些方法提高了血液筛检的检测能力。

此外，血液筛检技术的进步正在推动市场创新。自动化系统和就地检验解决方案的开发正在改变血液筛检的方式，从而加快检测速度并提高工作流程效率。这些创新不仅提高了检测准确性，还缩短了结果週转时间，使医疗服务提供者能够及时做出有关患者照护的决策。随着血液筛检市场的不断发展，持续的研发工作将在拓展检测解决方案范围以满足医疗服务提供者多样化需求方面发挥关键作用。

此外，对预防性医疗保健和早期检测的日益重视正在重塑血液筛检模式。随着人们对定期健康检查重要性的认识不断提高，患者越来越倾向于进行血液检测，以便在潜在健康问题恶化之前将其识别出来。医疗保健提供者也认识到主动筛检在慢性病管理和改善患者预后的价值。随着血液筛检市场的持续成长，技术进步、患者意识的提高以及对预防性医疗保健的重视将在推动未来成长方面发挥关键作用。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球血液筛检市场（依技术划分）

• 市场分析、洞察与预测
• 核酸增幅检查（NAT）
• ELISA
• 化学冷光免疫检测（CLIA 和 EIA）
• 次世代定序（NGS）
• 蛋白质印迹法（WB）

5. 全球血液筛检市场（依产品划分）

• 市场分析、洞察与预测
• 试剂
• 装置

6. 全球血液筛检市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott
  • Danaher Corporation（Beckman Coulter）
  • Becton Dickinson And Company
  • Bio-Rad LaboratoriesInc
  • Hoffman-La Roche Ltd
  • Grifols, SA
  • Ortho-Clinical DiagnosticsInc
  • Siemens Healthcare GmbH
  • Thermo Fisher ScientificInc
  • SOFINA SA（Biomerieux）

The Blood Screening Market size is expected to reach USD 11.31 Billion in 2034 from USD 3.88 Billion (2025) growing at a CAGR of 12.62% during 2026-2034.

The blood screening market is poised for significant growth, driven by the increasing prevalence of infectious diseases and the rising demand for safe blood transfusions. Blood screening is a critical process that ensures the safety of blood products by detecting pathogens, antibodies, and other harmful substances. As healthcare providers prioritize patient safety and regulatory bodies enforce stringent testing requirements, the adoption of advanced blood screening technologies is expected to rise. This market is witnessing a shift towards more efficient and accurate testing methods, including nucleic acid testing (NAT) and multiplex assays, which enhance the detection capabilities of blood screening processes.

Moreover, advancements in blood screening technologies are propelling innovation within the market. The development of automated systems and point-of-care testing solutions is transforming the way blood screening is conducted, allowing for faster results and improved workflow efficiency. These innovations not only enhance the accuracy of testing but also reduce the turnaround time for results, enabling healthcare providers to make timely decisions regarding patient care. As the blood screening market continues to evolve, ongoing research and development efforts will play a crucial role in expanding the range of testing solutions available to meet the diverse needs of healthcare providers.

Additionally, the growing emphasis on preventive healthcare and early detection is shaping the blood screening landscape. As awareness of the importance of regular health screenings increases, patients are more likely to seek out blood tests that can identify potential health issues before they escalate. Healthcare providers are also recognizing the value of proactive screening in managing chronic conditions and improving patient outcomes. As the blood screening market continues to grow, the combination of technological advancements, increasing patient awareness, and a focus on preventive care will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA & EIA )
• Next Generation Sequencing (NGS)
• Western Blotting (WB)

By Product

• Reagent
• Instrument

COMPANIES PROFILED

• Abbott, Danaher Corporation Beckman Coulter, Becton Dickinson and Company, BioRad Laboratories, Inc, HoffmanLa Roche Ltd, Grifols, SA, OrthoClinical Diagnostics, Inc, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc, SOFINA sa Biomerieux

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLOOD SCREENING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Nucleic Acid Amplification Test (NAT) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. ELISA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chemiluminescence Immunoassay (CLIA & EIA ) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Next Generation Sequencing (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Western Blotting (WB) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLOOD SCREENING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Reagent Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Instrument Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLOOD SCREENING MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Technology
  • 6.2.2 By Product
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Technology
  • 6.3.2 By Product
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Technology
  • 6.4.2 By Product
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Technology
  • 6.5.2 By Product
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Technology
  • 6.6.2 By Product
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BLOOD SCREENING INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott
  • 8.2.2 Danaher Corporation (Beckman Coulter)
  • 8.2.3 Becton Dickinson And Company
  • 8.2.4 Bio-Rad LaboratoriesInc
  • 8.2.5 Hoffman-La Roche Ltd
  • 8.2.6 Grifols, S.A
  • 8.2.7 Ortho-Clinical DiagnosticsInc
  • 8.2.8 Siemens Healthcare GmbH
  • 8.2.9 Thermo Fisher ScientificInc
  • 8.2.10 SOFINA S.A (Biomerieux)